Orally Administered DTPA Penta‐Ethyl Ester for the Decorporation of Inhaled 241Am. Issue 5 (11th March 2014)

• Record Type: Journal Article
• Authors: Sueda, Katsuhiko; Sadgrove, Matthew P.; Huckle, James E.; Leed, Marina G. D.; Weber, Waylon M.; Doyle‐Eisele, Melanie; Guilmette, Raymond A.; Jay, Michael
• Is Part Of: Journal of pharmaceutical sciences. Volume 103:Issue 5(2014:May)
• Page Start: 1563
• Page End: 1571
• Publication Date: 2014-03-11
• Subjects: Pharmacy -- Periodicals; 615.1
• DOI: 10.1002/jps.23932
• Languages: English
• ISSNs: 0022-3549

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Diethylenetriaminepentaacetic acid (DTPA) is an effective decorporation agent to facilitate the elimination of radionuclides from the body, but its permeability‐limited oral bioavailability limits its utility in mass‐casualty emergencies. To overcome this limitation, a prodrug strategy using the penta‐ethyl ester form of DTPA is under investigation. Pharmacokinetic and biodistribution studies were conducted in rats by orally administering [<sup>14</sup>C]DTPA penta‐ethyl ester, and this prodrug and its hydrolysis products were analyzed as a single entity. Compared with a previous reporting of intravenously administered DTPA, the oral administration of this prodrug resulted in a sustained plasma concentration profile with higher plasma exposure and lower clearance. An assessment of the urine composition revealed that the bioactivation was extensive but incomplete, with no detectable levels of the penta‐ or tetra‐ester forms. Tissue distribution at 12 h was limited, with approximately 73% of the administered dose being associated with the gastrointestinal tract. In the efficacy study, rats were exposed to aerosols of <sup>241</sup>Am nitrate before receiving a single oral treatment of the prodrug. The urinary excretion of <sup>241</sup>Am was found to be 19% higher than with the control. Consistent with prior reports of DTPA, the prodrug was most effective when the treatment delays were minimized. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:1563–1571, 2014</p> </abstract>